Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
Potential biomarkers for malignant melanoma
Ye-Nan Wang, Yuki Yamamoto, Fukumi Furukawa, Department of Dermatology, Wakayama Medical University, Wakayama 641-0012, Japan
Author contributions: Wang YN wrote this manuscript and made the figure; Yamamoto Y contributed to the writing of this manuscript; Furukawa F critically revised this manuscript.
Correspondence to: Ye-Nan Wang, MD, Department of Dermatology, Wakayama Medical University, 811-1, Kimiidera, Wakayama City, Wakayama 641-0012, Japan. wangyenan1112@live.cn
Telephone: +81-73-4472300 Fax: +81-73-4481908
Received: July 7, 2013
Revised: August 14, 2013
Accepted: September 3, 2013
Published online: November 2, 2013
Revised: August 14, 2013
Accepted: September 3, 2013
Published online: November 2, 2013
Core Tip
Core tip: Melanoma is one of the most common cancers and its high metastatic potential has a large impact on the number of melanoma deaths. Emerging molecular knowledge may lead to further identification of clinically relevant biomarkers, such as S100B, MIA, TA-90IC, 5-S-CD, SPARC, CSPG4, HSP105, IMP3, KIF2A, miR-221, YKL-40, some cancer stem cells (CD133, Nestin, CD166, CD20, CD271) and some monoclonal antibodies (KBA62, PNL2), for malignant melanoma detection, risk stratification and prediction/prognosis. However, all current markers have some shortcomings and thus we expect there will be more novel melanoma biomarkers discovered as supplementary diagnostic criteria in the near future.